Frazier Life Sciences Management, L.P.

Q3 2026 13F-HR Holdings

Location
Palo Alto, CA
Holdings as of
9/30/2026
Date filed
11/16/2026
Form type
13F-HR
Num holdings
44
Total value ($000)
$4,030,605
Net value change ($000)
-561,472 (-12.2%)
New positions
7
Sold out positions
4
Turnover %
16.2%
Sector allocation + QoQ delta (equities-only)

Snapshot: Change Analysis

Compared to Q2 2026
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
ATTOVIA THERAPEUTICS INC 120,773 NEW
BRAVEHEART BIO INC 106,400 NEW
Ascendis Pharma AS 51,297 NEW
MNKD 33,330 118.5%
CLDX 29,172 NEW
MBX 22,750 6.2%
PARABILIS MEDICINES INC 22,688 43.2%
ACRS 19,862 76.2%
SRPT 19,495 NEW
ZLAB 13,963 38.6%
Top Reduces (Value $000, Stocks/ETFs)
MIRM -242,602 -27.0%
NAMS -151,223 -24.7%
BBIO -115,305 -100.0%
CYTK -98,810 -100.0%
ASND -60,053 -100.0%
SVRA -54,133 -90.4%
TRVI -48,770 -26.3%
KRYS -48,750 -27.3%
PHAT -44,256 -32.7%
IRON -37,899 -38.2%
Instrument mix + QoQ Δ (ex-options)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type